The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

2.

FDA Approves Hemophilia B Second Gene Therapy.

3.

Experts Discuss Groundbreaking Advances in EGFR-Mutant Lung Cancer

4.

Study indicates that exercise can help colon cancer survivors live as long as matched individuals

5.

Study finds that AI is better at forecasting the risk of developing cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot